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Abstract
Objectives Oesophageal adenocarcinoma has a poor prognosis and relies on multi-modality assessment for accurate nodal
staging. The aim of the study was to determine the prognostic significance of nodal concordance between PET/CT and EUS
in oesophageal adenocarcinoma.
Methods Consecutive patients with oesophageal adenocarcinoma staged between 2010 and 2016 were included. Groups com-
prising concordant node–negative (C−ve), discordant (DC), and concordant node–positive (C+ve) patients were analysed.
Survival analysis using log-rank tests and Cox proportional hazards model was performed. The primary outcome was overall
survival. A p value < 0.05 was considered statistically significant.
Results In total, 310 patients (median age = 66.0; interquartile range 59.5–72.5, males = 264) were included. The median overall
survival was 23.0 months (95% confidence intervals (CI) 18.73–27.29). There was a significant difference in overall survival
between concordance groups (X2 = 44.91, df = 2, p < 0.001). The hazard ratios for overall survival of DC and C+ve patients
compared with those of C−ve patients with cT3 tumours were 1.21 (95% CI 0.81–1.79) and 1.79 (95% CI 1.23–2.61), respec-
tively. On multivariable analysis, nodal concordance was significantly and independently associated with overall survival (HR
1.44, 95% CI 1.12–1.83, p = 0.004) and performed better than age at diagnosis (HR 1.02, 95% CI 1.003–1.034, p = 0.016) and
current cN-staging methods (HR 1.20, 95% CI 0.978–1.48, p = 0.080).
Conclusions Patients with discordant nodal staging on PET/CT and EUS represent an intermediate-risk group for overall sur-
vival. This finding was consistent in patients with cT3 tumours. These findings will assist optimum treatment decisions based
upon perceived prognosis for each patient.
Key Points
• Clinicians are commonly faced with results of discordant nodal staging in oesophageal adenocarcinoma.
• There is a significant difference in overall survival between patients with negative, discordant, and positive lymph node staging.
•Patients with discordant lymph node staging between imagingmodalities represent an intermediate-risk group for overall survival.
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Abbreviations
C−ve Concordant negative nodal status
C+ve Concordant positive nodal status
CI Confidence intervals
CT Computed tomography
cM-stage Clinical M-stage
cN-stage Clinical N-stage
cT-stage Clinical T-stage
DC Discordant nodal status
dCRT Definitive chemoradiotherapy
EMR Endoscopic mucosal resection
EUS Endoscopic ultrasound
GOJ Gastro-oesophageal junction
HR Hazard ratio
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Introduction
Oesophageal cancer is newly diagnosed in over 9000 people
in the United Kingdom (UK) each year and predominately of
adenocarcinoma cell type, with around 7 in 10 diagnosed at an
advanced stage [1]. Radiological staging is central to manage-
ment, planning, and prognosis, and usually involves a combi-
nation of computed tomography (CT), positron emission to-
mography combined with CT (PET/CT), and endoscopic ul-
trasound (EUS) [2].
Lymph node metastases are a major prognostic indicator in
oesophageal cancer [3, 4]. Nodal assessment therefore is a key
factor in radiological staging but the accuracy of these individ-
ual modalities is suboptimal [5, 6]. EUS is generally regarded as
the gold standard for assessment of regional lymph nodes, but
controversy regarding the role of EUS in staging exists. Studies
have shown limited benefits versus risk [7] whilst others sug-
gest EUS can impact treatment decisions in 29% of patients [8]
and reduce edge of radiotherapy field relapses when EUS mea-
surements are used to define gross tumour volume [9].
There is a lack of studies investigating the prognostic sig-
nificance of nodal concordance between imaging modalities
in oesophageal cancer staging. Diagnostic confidence is im-
proved when a node has malignant characteristics on more
than one imaging modality. The high specificity and positive
predictive value compared with low sensitivity and negative
predictive value of CT and PET/CT [10, 11] mean that a
lymph node is often considered to be involved if malignant
characteristics are demonstrated on multiple modalities.
However, clinicians face a difficult diagnostic conundrum
in cases where there are discordant findings of malignancy in
lymph nodes between different modalities. Important treat-
ment decisions often hinge on the classification of nodal me-
tastases on PET/CT and EUS examinations. In a previous
study, Dhupar et al [12] reviewed 615 patients with oesopha-
geal cancer from a single centre who underwent
oesophagectomy for survival outcomes based on concordance
of staging investigations for nodal disease. In summary, the
study found that patients with discordance in nodal staging
between imaging modalities had a better overall survival than
patients with positively concordant nodal staging. However,
more data is required to validate these findings.
Therefore, the aim of this study was to determine the prog-
nostic significance of nodal concordance between PET/CT
and EUS in oesophageal adenocarcinoma.
Materials and methods
Institutional review board approval was obtained for this
study (reference 13//DMD5769). We performed a retro-
spective review of a prospectively collected database of
patients with oesophageal adenocarcinoma in a regional
upper GI cancer network comprising four health boards
and eight different centres.
Consecutive patients (n = 420) were considered for this
study. Inclusion criteria were patients with biopsy-
confirmed adenocarcinoma of the oesophagus or gastro-
oesophageal junction (GOJ) who were staged with
contrast-enhanced CT, PET/CT, and EUS between 2010
and 2016. Exclusion criteria were a histological cell type
other than adenocarcinoma, those who did not have PET/
CT (n = 2) or EUS (n = 89; n = 71 because of M1 disease
on PET/CT and n = 18 due to non-traversable stenotic tu-
mour), patients with missing TNM staging data (n = 17),
and patients with missing survival data (n = 2). Following
exclusion criteria application, 310 patients were included.
During the study period, patients were staged according to
TNM 7th edition [13]. Use of the TNM 8th edition [14]
would not have altered stage groupings.
Staging pathway
Patients are usually diagnosed with oesophageal cancer
following upper GI endoscopy and biopsy. Patients then
undergo a contrast-enhanced CT of the thorax, abdomen,
and pelvis to assess for distant metastases. If the patient
was considered to have potentially curable disease after
staging CT (i.e. absence of M1 disease), then more de-
tailed staging with PET/CT and EUS was performed. EUS
was not completed in patients with a non-traversable ste-
notic tumour and not performed in patients with con-
firmed M1 disease on PET/CT. The PET/CT and EUS
protocols are available in the supplementary material.
Clinical T-stage
Following multi-disciplinary team (MDT) review, clinical T-
stage (cT-stage) was assigned to each patient following con-
sideration of the contrast-enhanced CT and EUS findings,
with the latter being considered the most accurate modality
for cT-stage [15].
Definition of positive lymph node metastasis
On PET/CT, nodes were classed as involved if identified
on the CT component and showed FDG uptake appreciably
higher than background values. No specific standardised
uptake value was used to diagnose regional nodes because
this decision is subjective and multi-factorial. Lymph
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nodes considered physiological or related to an alternative
aetiology were excluded from the N-stage. On EUS, the
criteria for malignant lymphadenopathy specified a
hypoechoic pattern, spherical contour, distinct border, and
a short-axis diameter of 6 mm or more. PET/CT and EUS
cN-staging were collected from the clinical radiology re-
ports which were used to decide the subsequent treatment.
Overall clinical N-stage (cN-stage) was assigned following
MDT review after consideration of the combined CT, PET/
CT, and EUS findings.
Definition of concordance
Three classifications were defined for this study. Nodal
concordance was defined as either negative (C−ve) or
positive (C+ve). C−ve patients had cN0 disease on both
PET/CT and EUS and C+ve patients had cN+ disease on
both modalities. Discordant patients (DC) had cN0 dis-
ease on one modality but not the other (Fig. 1). Further
subgroups were constructed based on modality findings;
PET/CT−ve:EUS+ve and EUS−ve:PET/CT+ve.
Survival data
The primary outcome of the study was overall survival, de-
fined as the length of survival following diagnosis until death
or date of last follow-up. Survival data was obtained from the
Cancer Network Information System database. Patients are
followed up at regular intervals following radical treatment,
every 3 months for the first year and then 6-monthly thereafter
for the next 4 years.
Statistical analysis
Descriptive statistics were expressed as frequency
(percentage) for categorical variables and median (inter-
quar t i le range (IQR)) for cont inuous var iables .
Differences between categorical variables and continuous
variables were assessed using chi-square tests and Mann-
Whitney U tests, respectively. Median overall survival was
estimated using the Kaplan-Meier life-table method [16].
Mean overall survival was calculated when median overall
survival was not reached. Cumulative survival curves were
generated and differences between groups evaluated with
the log-rank test. The prognostic significance of cT-stage
and cN-stage were evaluated using this method. Hazard
ratios were calculated with a Cox proportional hazards
model and compared with the baseline group. A subgroup
analysis for curative versus palliative treatment groups was
pre-specified and performed separately. Multivariable
analysis evaluated whether age at diagnosis, nodal concor-
dance, or current cN-staging methods were the better pre-
dictor of overall survival. Statistical analysis was per-
formed using SPSS v23.0 (IBM). A p value < 0.05 was
considered statistically significant.
Fig. 1 Clinical example of
discordant radiological lymph
node staging. A patient with a
primary distal oesophageal
adenocarcinoma had a 9-mm
lymph node (white arrows) on (a)
a contrast-enhanced CT and (b) a
PET/CTwith minimally increased
SUV (2.6) compared with
background. An (c) EUS was
performed which shows a
malignant appearance (8 mm,
round and hypoechoic), and a fine
needle aspiration (FNA) was
performed. The (d) FNAwith
papanicolaou stain at × 40
magnification showed
adenocarcinoma cells from the
lymph node (large pleomorphic
cells with prominent nucleoli in a
cohesive group)
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Results
The baseline characteristics of included patients are de-
tailed in Table 1. The median age of the cohort was
66.0 years (IQR 59.5–72.5). The median overall survival
was 23.0 months (95% confidence intervals (CI) 18.73–
27.29). One-, 2-, and 5-year overall survival rates were
73.5% (n = 228/310; 95% CI 73.45–73.55), 48.4% (n =
150/310; 95% CI 48.35–48.45), and 13.5% (n = 42/310;
95% CI 13.44–13.55), respectively. The median follow-up
was 63.0 months (95% CI 57.97–68.04).
A large number of patients (n = 89) were initially excluded
because of missing EUS data; therefore, comparison of base-
line characteristics was performed in these patients. Age (t =
1.518, mean difference 1.738 (95% CI − 0.513–3.988), p =
0.130), gender (X2 0.003, df 1, p = 0.957), and tumour loca-
tion (X2 0.239, df 1, p = 0.625) were not significantly different
between patient groups with and without EUS staging.
Prognostic significance of nodal concordance
between PET/CT and EUS
The median overall survival for C−ve, DC, and C+ve pa-
t ients were 43.0 months (95% CI 33.22–52.78),
21.0 months (95% CI 9.36–32.64), and 13.0 months
(95% CI 11.25–14.76), respectively. There was a signifi-
cant difference in overall survival between groups (X2
44.91, df 2, p < 0.001) (Fig. 2). Furthermore, there were
significant differences between C−ve and DC groups (X2
5.18, df 1, p = 0.023) and DC and C+ve groups (X2 11.11,
df 1, p = 0.001). The hazard ratios for overall survival of
DC and C+ve patients compared with those of C−ve pa-
tients overall were 1.46 (95% CI 1.04–2.06) and 2.66 (95%
CI 1.97–3.60), respectively. This suggests that patients
with discordant nodal staging between PET/CT and EUS
represent an intermediate-risk group for overall survival.
Prognostic significance of cT-stage and cN-stage
In this cohort, cT-stage (X2 54.12, df 4, p < 0.001) and cN-
stage (X2 48.85, df 3, p < 0.001) were significantly asso-
ciated with overall survival. The hazard ratios for overall
survival of N1, N2, and N3 stages compared with those of
N0 were 1.57 (95% CI 1.14–2.15), 3.13 (2.19–4.49), and
2.60 (1.65–4.09), respectively. Survival statistics are pre-
sented for each cT-stage in Table 2.
There was a significant difference between C−ve, DC, and
C+ve patients staged with cT3 tumours (X2 10.19, df 2, p =
0.006) (Fig. 3). cT3 was significantly associated with overall
survival but other cT-stages were not, likely due to the small
numbers included. The hazard ratios for overall survival of
DC and C+ve patients compared with those of C−ve patients
with cT3 tumours were 1.21 (95% CI 0.81–1.79) and 1.79
(95% CI 1.23–2.61), respectively. No significant difference
in overall survival was found between C−ve and DC (X2
0.94, df 1, p = 0.33), groups but there was a significant differ-
ence between DC and C+ve (X2 3.19, df 1, p = 0.048) groups,
suggesting that DC patients with cT3 tumours have similar
survival to C−ve patients.
Table 1 Baseline characteristics of patient cohort
Clinical variable Frequency (%)
Gender
Male 264 (85.2)
Female 46 (14.8)
Tumour location
Oesophagus 158 (51.0)
Mid oesophagus 27 (17.1)
Distal oesophagus 131 (82.9)
GOJ 152 (49.0)
Siewert type I 60 (39.5)
Siewert type II 44 (28.9)
Siewert type III 48 (31.6)
Grade of differentiation
Well 21 (6.8)
Moderate 97 (31.3)
Poor 116 (37.4)
GX 76 (24.5)
cT-stage
T1 29 (9.4)
T2 34 (11.0)
T3 202 (65.2)
T4a 41 (13.2)
T4b 4 (1.3)
cN-stage
N0 132 (42.6)
N1 96 (31.0)
N2 54 (17.4)
N3 28 (9.0)
cM-stage
M0 310 (100)
Treatment
Radical 222 (71.6)
NACT 94 (42.3)
dCRT 56 (25.2)
Surgery alone 48 (21.6)
NACRT 20 (9.0)
EMR 4 (1.8)
Palliative 88 (28.4)
GOJ, gastro-oesophageal junction; GX, grade not assessed; cT-stage,
clinical tumour stage; cN-stage, clinical regional nodal stage; cM-stage,
clinical metastatic stage; NACT, neoadjuvant chemotherapy; dCRT, de-
finitive chemoradiotherapy; NACRT, neoadjuvant chemoradiotherapy;
EMR, endoscopic submucosal resection
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Differences between PET/CT and EUS nodal staging
The relationship between PET/CT and EUS N-staging was
examined by creating two groups: (1) PET/CT−ve:EUS+ve
and (2) EUS-ve:PET/CT+ve. In total, 16/310 patients (5.2%)
had PET/CT cN+ and EUS cN0 disease. Conversely, 57/310
patients (18.4%) had EUS cN+ and PET/CT cN0 disease.
There was a significant difference in frequency between these
two groups (X2 97.29, df 1, p < 0.001). In addition, there were
significant differences between C−ve, PET/CT−ve:EUS+ve,
EUS-ve:PET/CT+ve, and C+ve groups (X2 50.99, df 3,
p < 0.001) (Fig. 4). The median overall survival for the
EUS-ve:PET/CT+ve group was 14.0 months (95% CI
12.70–15.30) and 34.0 months (95% CI 13.92–54.08) for
the PET/CT−ve:EUS+ve group. There was a significant
difference between PET/CT−ve:EUS+ve and EUS-
ve:PET/CT+ve groups (X2 6.50, df 1, p = 0.011) suggest-
ing patients with PET/CT−ve:EUS+ve nodes had a better
outcome, although the numbers in the PET/CT+ve:EUS-
ve group were relatively low.
Subgroup analysis
With different treatment regimens included in this study, a sub-
group analysis compared the prognostic significance of nodal
concordance between patients treated with radical versus palli-
ative treatments. There was a significant difference in overall
survival between C−ve, DC, and C+ve nodal concordance
when adjusting for treatment intent (X2 13.88, df 1, p =
0.001), demonstrating that the discordant group remained at
intermediate risk in both radical and palliative settings. The
median overall survival for patients treated with radical versus
palliative intent was 37.0 months (95% CI 28.77–45.23) and
12.0 months (95% CI 10.04–13.97), respectively. Furthermore,
there were no significant differences in overall survival (X2
6.977, df 4, p = 0.137) between radical treatment groups (neo-
adjuvant chemotherapy (NACT), definitive chemoradiotherapy
(dCRT), surgery alone, neoadjuvant chemoradiotherapy
(NACRT), and endoscopic mucosal resection (EMR)).
The hazard ratios for overall survival of DC and C+ve pa-
tients compared with those of C−ve in patients treated with
Table 2 Comparison of cT-stage
between negative concordance,
discordance, and positive concor-
dance groups
T-stage Concordance Frequency (%) Median OS (months) (95% CI) X2 df p value
T1 (n = 29) C−ve 29 (100) *79.22 (64.85–93.59) - - -
DC 0 -
C+ve 0 -
T2 (n = 34) C−ve 25 (73.5) 40.0 (25.31–54.69) 2.44 2 0.295
DC 5 (14.7) 67.0 (67.0–67.0)
C+ve 4 (11.8) 9.0 (7.04–10.96)
T3 (n = 202) C−ve 71 (35.1) 33.0 (24.74–41.26) 10.19 2 0.006
DC 61 (30.2) 22.0 (7.79–36.21)
C+ve 70 (34.7) 14.0 (7.85–20.15)
T4a (n = 41) C−ve 8 (19.5) 16.0 (6.30–25.70) 4.29 2 0.117
DC 5 (12.2) 15.0 (8.56–21.44)
C+ve 28 (68.3) 12.0 (10.52–13.48)
T4b (n = 4) C−ve 1 (25.0) *41.0 (41.00–41.00) 3.34 2 0.188
DC 1 (25.0) *8.0 (8.00–8.00)
C+ve 2 (50.0) *6.5 (5.52–7.48)
*Mean OS; OS, overall survival; X2 , chi-square statistic; df, degrees of freedom; C−ve, negative node concor-
dance; DC, nodal discordance; C+ve, positive node concordance
Fig. 2 KM plot showing
cumulative survival curves for
C−ve, DC, and C+ve patients (X2
44.91, df 2, p < 0.001)
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radical intent were 1.24 (95% CI 0.84–1.84) and 1.75 (95% CI
1.16–2.64), respectively. In palliative patients, the hazard ratios
for overall survival of DC and C+ve patients compared with
those of C−ve patients treated palliatively were 3.13 (95% CI
1.46–6.67) and 2.38 (95% CI 1.28–4.42), respectively. These
results show that the overall survival of DC patients more close-
ly matched C−ve patients when treated with radical intent, but
the opposite effect was true when treated palliatively.
Multivariable analysis
On multivariable analysis, age at diagnosis, nodal concordance,
and cN-stage were entered into a multi-variable model. Nodal
concordancewas significantly and independently associatedwith
overall survival (HR 1.44, 95% CI 1.12–1.83, p = 0.004) and
performed better than age at diagnosis (HR 1.02, 95% CI
1.003–1.034, p = 0.016) and current cN-staging methods (HR
1.20, 95% CI 0.978–1.48, p= 0.080).
Discussion
This study has shown that patients with discordant nodal stag-
ing on PET/CT and EUS represent an intermediate-risk group
for overall survival. This finding is important when deciding
upon the optimum treatment decision based upon the per-
ceived risk stratification for each patient [17].
Cliniciansarecommonlyfacedwithresultsofdiscordant lymph
node staging between imaging modalities. Accurate detection of
lymphnodemetastases is important for staging andprognosis, and
their detection changes treatment decisions. In this cohort,wehave
demonstrated the prognostic significance of cT- and cN-stage.
However, clinical ambiguity is introduced into decision pathways
if twomodalities (PET/CTandEUS) are discordant. This ambigu-
itycancreatediagnosticandmanagementuncertainty forclinicians
whomust judgethemostappropriatetreatmentconsideringthebest
interests of each patient. In such cases, a discordant lymph node is
often considered likely to be metastatic given the incidence of
Fig. 3 Cumulative survival
curves for C−ve, DC, and C+ve
patients with cT3 tumours (X2
10.19, df 2, p = 0.006)
Fig. 4 Cumulative survival
curves for C−ve, PET/CT−ve:
EUS+ve, EUS-ve:PET/CT+ve,
and C+ve patients (X2 50.99, df 3,
p < 0.001)
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metastases with advanced cT-stage [3] and the higher specificity
and positive predictive value of CTand PET [11].
These results are consistent with data from a cohort of
oesophageal cancer patients who underwent oesophagectomy
[12]. This study also described an intermediate-risk group
comprising patients with discordant staging investigations,
in which DC patients had better over survival than C+ve pa-
tients. Despite the findings of our current study, the literature
surrounding the prognostic significance of discordant lymph
node staging is sparse.
Importantly, this study has further shown the significant
overall survival differences between C−ve, DC, and C+ve
groups in patients with cT3 tumours. These data could be used
to support clinical decisions in patients with cT3 tumours,
which is the most common stage of oesophageal tumours at
presentation [18]. Overall survival for patients with cT4 tu-
mours was not found to be statistically significant between cT-
stage groups, but this is likely to be an effect of small patient
numbers in this subgroup. Patients with nodal discordance had
an overall survival probability more closely aligned to patients
with C−ve nodes, suggesting that in these cases, clinicians
should place the findings in a wider clinical context and per-
haps consider more radical treatment.
The subgroup analysis found that discordant nodal staging
had a better prognosis in patients treated with radical intent but
a worse prognosis in patients treated palliatively. These find-
ings are likely to be biased by the retrospective nature of this
study and influenced by the effects of treatment, which are
broadly based on a number of clinical, physiological, radio-
logical, and pathological factors. Endoscopic mucosal resec-
tion (EMR) is available for patients with limited early-stage
disease. No survival benefit from EMR was demonstrated in
this study, but only four EMR patients were included in this
cohort. Fit, young patients may have been treated more ag-
gressively than those with a significant number of comorbid-
ities. In the latter cases, clinicians may have decided that the
discordance added further uncertainty that the effects of radi-
cal treatment would be beneficial. This confounding bias can-
not be adjusted for in retrospective studies, and these findings
will need to be validated in prospective studies.
The number of patients classified with positive lymph
nodes (cN+) is often higher on EUS than on PET/CT [15],
and this trend was shown again here. PET imaging is lim-
ited in its ability to detect small and peri-tumoural lymph
node metastases because of the relatively large spatial res-
olution and reliance on co-registration for anatomical def-
inition [19]. In addition, the positive correlation between
primary tumour and lymph node uptake means that metas-
tases are less likely to be detected if the primary tumour
demonstrates low FDG uptake. Overall, recent data has
shown that the sensitivity of CT, PET/CT, and EUS is poor
(39.7%, 35.3%, and 42.6%, respectively) [5], which is con-
sistent with data from other specialist oesophageal cancer
centres [6] and different thoracic tumour sites such as non–
small cell lung cancer [20].
Similarly, there was a significant difference in overall sur-
vival between PET/CT−ve:EUS+ve and EUS-ve:PET/CT+ve
groups, suggesting that patients with PET/CT−ve:EUS+ve
discordant nodes had a better outcome, although the numbers
in the PET/CT−ve:EUS+ve were low. Overall, these results
show that clinicians should refrain from instinctively conclud-
ing that a discordant lymph node is metastatic. False-positive
rates of CT, PET/CT, and EUS range between 15 and 30% for
cN-staging [10].
New methods to improve lymph node metastasis staging
accuracy are required because radiological techniques alone
are unlikely to improve sufficiently in the near future. A high
proportion of micro-metastases (82%) have been detected in
normal-sized lymph nodes of patients with oesophageal can-
cer [5], and it is believed that micro-metastases are associated
with a poorer clinical outcome [21], although the evidence is
conflicting. At present, micro-metastases cannot be visualised
on current imaging modalities.
The false-positive rates of each modality and high propor-
tion of metastases highlight that lymph node staging should be
considered within a multi-disciplinary context, with factors
such as lymph node location and number, grade of primary
tumour differentiation, and underlying tumour biology known
to have prognostic significance [22].
Strengths
This study includes a large consecutive cohort of fully staged
patients from a large regional upper GI cancer network serving
a population of approximately 1.5 million. The overall surviv-
al data are robust and no patient was lost to follow-up. A
comparison of cT-stage and radical versus palliative care treat-
ment subgroups demonstrated that the prognostic significance
of discordant lymph nodes was consistent.
Limitations
As discussed above, retrospective studies are likely to be
hindered by confounding biases. Individual lymph nodes
were not examined; rather, the cN-stage between modali-
ties was compared on a per-patient basis. Histopathological
correlation was not possible in the majority of the cohort
because relatively few patients are suitable for surgical
resection. Contrast-enhanced CT data were not analysed
in this study because it is known that the accuracy of CT
N-staging is poor and the PET/CT has a CT component
which was used at the time of reporting to evaluate indi-
vidual lymph nodes. Lastly, squamous cell carcinoma was
not included because this study focussed on adenocarcino-
ma, the most prevalent histological cell type in European
and North American countries [23].
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In conclusion, this study has shown that patients with dis-
cordant nodal staging on PET/CT and EUS represent an
intermediate-risk group for overall survival and have better
survival rates than those with positively concordant lymph
nodes. This finding was consistent in patients with cT3 tu-
mours and is important when deciding upon the optimum
treatment based upon the perceived prognosis for each patient.
These results should be validated in prospective studies.
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